CJC-1295 With DAC vs Without DAC: What Does the Research Show?

A research comparison of CJC-1295 with DAC (extended half-life) vs CJC-1295 without DAC (mod GRF 1-29). Pharmacokinetics, GH release patterns, and research applications.

By Research Vials Science Team | | 10 min read

CJC-1295 exists in two distinct research formulations that produce fundamentally different pharmacokinetic profiles. The choice between them depends entirely on whether the research question requires sustained GH elevation or pulsatile, physiological GH release — a distinction with significant implications for study design.

What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH), specifically a modified version of GRF(1-29) with amino acid substitutions at positions 2, 8, 15, and 27 that improve metabolic stability. The base peptide binds the GHRH receptor on anterior pituitary somatotrophs, stimulating GH synthesis and secretion.

The DAC Technology

The Drug Affinity Complex is a chemical modification — specifically, a maleimidopropionic acid moiety linked via a lysine residue — that enables the peptide to covalently bind to circulating albumin after injection. Since albumin has a half-life of ~20 days, this "albumin-hitchhiking" strategy dramatically extends the peptide's circulating duration from approximately 30 minutes to 6-8 days.

Pharmacokinetic Comparison

ParameterCJC-1295 With DACCJC-1295 Without DAC
Half-life6-8 days~30 minutes
GH release patternSustained elevationPulsatile
IGF-1 elevationProlonged (days)Transient (hours)
Dosing frequency1-2x per week in studies1-3x daily in studies
Physiological relevanceLess (tonic elevation)More (mimics natural pulses)

When to Use CJC-1295 With DAC

The DAC version is appropriate for research requiring sustained, chronic GH/IGF-1 elevation — such as long-term anabolic studies, chronic growth-factor exposure models, or protocols where minimizing injection frequency is methodologically important. Teichman et al. (2006) showed a single injection of CJC-1295-DAC elevated GH levels for 6+ days and IGF-1 for 9-11 days in human subjects (Teichman et al., 2006; PMID: 16352683).

When to Use CJC-1295 Without DAC

The non-DAC version (mod GRF 1-29) is preferred for research requiring physiological pulsatile GH release. Natural GH secretion occurs in pulses, primarily during deep sleep, and many GH-dependent processes respond differently to pulsatile vs. tonic exposure. For studies of GH-axis physiology, circadian GH patterns, or protocols combining with GH secretagogues like Ipamorelin, the non-DAC version provides a more interpretable stimulus.

Both Available at Research Vials

CJC-1295 With DAC 5mg and CJC-1295 Without DAC 10mg are both available at researchvials.com.

References

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683

Frequently Asked Questions

Research Use Only Disclaimer: All products referenced in this article are sold exclusively for laboratory research purposes. They are not intended for human or veterinary use, food additive use, drug use, or household use. This article is educational content based on published preclinical literature and does not constitute medical advice.

Share This Article

Related Research Products

RUO CJC-1295 – With DAC (5mg)
popular peptides

CJC-1295 – With DAC (5mg)

A GHRH analog conjugated with a Drug Affinity Complex for extended half-life, researched for sustained growth hormone el...

RUO CJC-1295 Without DAC (10mg)
popular peptides

CJC-1295 Without DAC (10mg)

A modified GRF(1-29) analog without the Drug Affinity Complex, studied for pulsatile GH release patterns and shorter hal...

RUO Ipamorelin (10mg)
popular peptides

Ipamorelin (10mg)

A selective growth hormone secretagogue that acts on the ghrelin receptor (GHS-R), studied for its ability to stimulate ...